Genetics Generation Advancement Corp is a Taiwan-based company mainly engaged in the development and introduction of digital data management systems for genetic testing, biology, chemistry and material consulting. Genetic testing services include pre-pregnancy and pregnancy testing, newborn testing, hereditary health and cancer screening and adult health management, and comprehensive genetic testing. Molecular digital services include software and database products, laboratory electronic management systems, enterprise quality management systems, scientific professional databases, scientific consulting services.

Employees

104

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-19	NT$38.00	-2.06%	60,956
26-10-16	NT$38.80	+1.31%	12,460
26-10-15	NT$38.30	-1.03%	88,242
26-10-14	NT$38.70	-0.77%	19,344
26-10-13	NT$39.00	0.00%	54,634

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-19			5-day change	1st Jan Change
38.00 ^TWD	-2.06%		-2.31%	-19.91%

08-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1.06B 32.78M 29.2M 27.07M 24.61M 46.19M 3.11B 47M 325M 127M 1.62B 123M 120M 5.2B	P/E 2024	33.6x	P/E 2025	62.3x
Enterprise Value	736M 22.67M 20.2M 18.73M 17.02M 31.95M 2.15B 32.51M 224M 88.18M 1.12B 85.08M 83.27M 3.59B	EV / Sales 2024	2.2x	EV / Sales 2025	1.66x
Free-Float	62.11%	Yield 2024	2.69%	Yield 2025	-

08-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-12	Genetics Generation Advancement Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-11	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-26	Genetics Generation Advancement Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-09	Genetics Generation Advancement Corp. announces Annual dividend, payable on October 31, 2025	CI
24-11-13	Genetics Generation Advancement Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Genetics Generation Advancement Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-14	Genetics Generation Advancement Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-03-25	Genetics Generation Advancement Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-04	Genetics Generation Advancement Corp. announces Annual dividend, payable on October 25, 2024	CI

22-08-15	Genetics Generation Advancement : Announcement of the record date of cash dividend	PU
22-08-05	Genetics Generation Advancement : Announcement of the Partial Correction of the Company's 2021 Annual Report	PU
22-08-03	Genetics Generation Advancement : To announce that 2022Q2 Consolidated Financial Statement approved by the Board of Directors	PU
22-03-17	Genetics Generation Advancement : Announce the release of non-competition restriction on managerial officer by the Board of Directors	PU
22-03-17	Genetics Generation Advancement : Announce the change of the company’s Spokesperson,Financial Officer,Accounting Officer and Corporate Governance Officer	PU

Genetics Generation Advancement Corp. Stock

Stocks

4160

TW0004160007

Biotechnology & Medical Research

Valuation: Genetics Generation Advancement Corp.

Chart: Genetics Generation Advancement Corp.

Latest news: Genetics Generation Advancement Corp.

Press Releases: Genetics Generation Advancement Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Genetics Generation Advancement Corp.

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 day	-2.06%
1 week	-2.31%
Current month	-2.81%
1 month	-2.94%
3 months	-0.04%
6 months	-10.77%
Current year	-19.91%

1 week	37.55	39.1
1 month	37.55	40.35
Current year	36.73	54.31
1 year	36.73	55.93
3 years	33.51	143.74
5 years	19.91	143.74
10 years	16.79	143.74

Manager	Title	Age	Since
Ching Yuan Kang CEO	Chief Executive Officer	-	2024-03-04
Yu Chun Hsiao DFI	Director of Finance/CFO	-	2023-12-31
Tai Sheng Chang CTO	Chief Tech/Sci/R&D Officer	-	2010-02-28

Director	Title	Age	Since
Cheng Hsien Tsai BRD	Director/Board Member	-	2010-12-14
Wen Cheng Chang BRD	Director/Board Member	-	2011-10-31
Han Tung Chang CHM	Chairman	-	2011-10-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENETICS GENERATION ADVANCEMENT CORP.	-2.06%	-2.31%	-25.73%	+11.15%	33.5M
WUXI APPTEC CO., LTD.	+1.52%	-7.16%	+51.66%	+67.41%	65B
LONZA GROUP AG	+1.52%	+7.17%	+10.77%	+77.89%	51.2B
ARGENX SE	+0.30%	+0.19%	+2.53%	+56.14%	51.19B
IQVIA HOLDINGS INC.	-0.38%	+2.31%	+29.98%	+40.71%	43.93B
BEONE MEDICINES AG	+0.30%	+4.43%	+16.99%	+120.94%	41.96B
REVOLUTION MEDICINES, INC.	+2.35%	-4.01%	+236.69%	+497.21%	38.14B
CELLTRION, INC.	+2.16%	+10.36%	+18.92%	+59.70%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	+1.80%	25.2B
GENMAB A/S	+1.60%	+3.97%	+21.34%	+22.33%	22.5B
Average	+0.64%	-0.13%	+40.02%	+95.53%	37.24B
Weighted average by Cap.	+0.97%	+0.04%	+46.02%	+106.35%

	2024	2025
Net sales	662M 20.38M 18.16M 16.83M 15.3M 28.72M 1.93B 29.22M 202M 79.26M 1.01B 76.47M 74.85M 3.23B	603M 18.57M 16.54M 15.34M 13.94M 26.17M 1.76B 26.63M 184M 72.22M 920M 69.69M 68.21M 2.94B
Net income	54.7M 1.68M 1.5M 1.39M 1.26M 2.37M 160M 2.41M 16.68M 6.55M 83.44M 6.32M 6.19M 267M	21.37M 658K 586K 543K 494K 927K 62.47M 944K 6.52M 2.56M 32.6M 2.47M 2.42M 104M
Net Debt	-373M -11.47M -10.22M -9.47M -8.61M -16.16M -1.09B -16.45M -114M -44.61M -568M -43.05M -42.13M -1.82B	-328M -10.11M -9M -8.35M -7.59M -14.24M -959M -14.49M -100M -39.3M -501M -37.92M -37.11M -1.6B